Local Injection of Bevacizumab as an Alternative Method for Management of Recurrent Pterygium

AUTHORS

Hamid Khoshniat 1 , * , HR Jahadi Hosseini 2 , M Nejabat 2 , K Fatehi 2 , M Mosallaei 2

1 Assistant Professor,Department of Ophthalmology,Poostchi Eye Research Center,Shiraz University of Medical Sciences, [email protected], Fars, Iran

2 Department of Ophthalmology, Poostchi Eye Research Center,Shiraz University of Medical Sciences, Fars, Iran

How to Cite: Khoshniat H, Jahadi Hosseini H, Nejabat M, Fatehi K, Mosallaei M. Local Injection of Bevacizumab as an Alternative Method for Management of Recurrent Pterygium, Iran Red Crescent Med J. Online ahead of Print ; 11(3):306-311.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 11 (3); 306-311
Article Type: Research Article
Received: September 2, 2008
Accepted: February 3, 2009

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Surgery has so far been used for primary treatment of pterygium; however, one of the major limitations is its high recurrence rate. This study was performed to determine the effect of bevacizumab in recurrent pterygium.

 

Methods: Patients with recurrent pterygium were divided into two groups, receiving bevacizumab (Group 1) or normal saline (Group 2). They were evaluated for photophobia and any conjunctival congestion and were scored from 0 to 4 prior to any injection. The size of pterygium was assessed in relation to extension of pterygium on the cornea over the limbus. All patients were followed in regular 48 hour intervals weekly up to one month and then monthly up to 6 months after the injection.

 

Results: There were 50 patients in group 1 and 48 in group 2 and the mean age of the patients was 40.94±13.82 and 47.10±5.9 years, respectively with a male to female ratio of . The mean size of ptrygium was 52.84 in group 1 and 46.02 in group 2. In group 1, photophobia and conjunctival congestion were 59.53 and 61.27, respectively while in group 2, they were 39.16, and 37.24, respectively. In the first 48 hours, conjunctival congestion and photophobia were higher in group 1 but there was no significant difference regarding the size of pterygium. After one week, the scores were significantly lower in group 1 while the mean rank for the size of pterygium was 52.84 in group 1, and 46.02 in group 2. After 1 and 6 months, the scores were lower in group 1.

 

Conclusion Subconjunctival injection of bevacizumab can be considered as an effective temporary treatment in the management of recurrent pterygium in those who are not a candidate for secondary operation. It can decrease conjunctival congestion and photophobia and prevent further progression even in the long term.

 

Keywords

Bevacizumab Management Recurrent pterygium

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: